Skip to main content
Defence Therapeutics Inc. logo

Defence Therapeutics Inc. — Investor Relations & Filings

Ticker · DTC ISIN · CA24463V1013 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2026-04-25 Director's Dealing
Country CA Canada
Listing CSE DTC

About Defence Therapeutics Inc.

https://defencetherapeutics.com/

Defence Therapeutics Inc. is a biotechnology company focused on developing advanced cancer therapeutics by enhancing drug delivery. Its core technology is the proprietary Accum® platform, a precision intracellular drug-delivery system designed to overcome endosomal entrapment and ensure therapeutic agents reach their cellular targets. Accum® is applied to significantly boost the efficacy and safety of various biologics, including Antibody-Drug Conjugates (ADCs), Radiopharmaceuticals (Radioimmune Conjugates or rADCs), and vaccines. Preclinical models demonstrate that Accum® can increase the potency of enhanced therapies up to 60-fold, enabling safer and more effective first-line treatments. The company utilizes a licensing model for its ADC enhancement technology and actively develops novel radioimmune conjugate assets, aiming to transform existing and next-generation oncology treatments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Director's Dealing Classification · 1% confidence The document is a press release announcing the board’s approval to grant 200,000 restricted stock units (RSUs) to the CEO and Director, which constitutes an insider compensation transaction. This falls under reporting personal share transactions by directors/executives (insider deals). Thus, the appropriate category is Director’s Dealing (DIRS).
2026-04-25 English
News release - English.pdf
Remuneration Information Classification · 1% confidence The document is a corporate press release announcing the grant of restricted stock units to the CEO and Director, detailing executive compensation under the Company's Omnibus Incentive Plan. This falls squarely under executive remuneration information for top management. Therefore, it is classified as Remuneration Information (DEF 14A).
2026-04-25 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'REPORT ON VOTING RESULTS' and explicitly details the outcome of a vote held at a special meeting of shareholders regarding an arrangement (merger/acquisition). It provides specific vote counts and percentages for the resolution. This aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2026-01-28 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing an amendment to a credit agreement (specifically an extension of a maturity date). This relates to the company's financing structure and debt obligations. According to the provided definitions, updates on company financing activities or capital structure changes fall under the 'CAP' (Capital/Financing Update) category.
2026-01-28 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing the formation of a new Scientific Advisory Board (SAB) for Defence Therapeutics. While it mentions management and board-related personnel, it does not announce changes to the Board of Directors or senior management (which would be MANG). It is a general corporate announcement regarding company operations and strategy. Since it does not fit into specific categories like M&A, financial results, or dividends, and is a standard regulatory press release, it falls under the RNS (Regulatory Filings) category.
2025-12-04 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by Defence Therapeutics regarding their business strategy and technological developments in ADC drug delivery. It does not report financial results, dividends, or governance changes, nor is it a formal regulatory filing or report. It functions as a general corporate announcement/news release, which falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2025-11-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.